Drug Interactions With the Ca-ATPase From Sarco(Endo)Plasmic Reticulum (SERCA)

Overview

Journal Front Mol Biosci

Specialty Biology

Date 2018 Apr 27

PMID 29696147

Citations 24

Authors

Francesco Tadini-Buoninsegni

Serena Smeazzetto

Roberta Gualdani

Maria Rosa Moncelli

Affiliations

Soon will be listed here.

Abstract

The sarco(endo)plasmic reticulum Ca-ATPase (SERCA) is an intracellular membrane transporter that utilizes the free energy provided by ATP hydrolysis for active transport of Ca ions from the cytoplasm to the lumen of sarco(endo)plasmic reticulum. SERCA plays a fundamental role for cell calcium homeostasis and signaling in muscle cells and also in cells of other tissues. Because of its prominent role in many physiological processes, SERCA dysfunction is associated to diseases displaying various degrees of severity. SERCA transport activity can be inhibited by a variety of compounds with different chemical structures. Specific SERCA inhibitors were identified which have been instrumental in studies of the SERCA catalytic and transport mechanism. It has been proposed that SERCA inhibition may represent a novel therapeutic strategy to cure certain diseases by targeting SERCA activity in pathogens, parasites and cancer cells. Recently, novel small molecules have been developed that are able to stimulate SERCA activity. Such SERCA activators may also offer an innovative and promising therapeutic approach to treat diseases, such as heart failure, diabetes and metabolic disorders. In the present review the effects of pharmacologically relevant compounds on SERCA transport activity are presented. In particular, we will discuss the interaction of SERCA with specific inhibitors and activators that are potential therapeutic agents for different diseases.

Citing Articles

Altered Ca2+ responses and antioxidant properties in Friedreich's ataxia-like cerebellar astrocytes.

Marullo C, Croci L, Giupponi I, Rivoletti C, Zuffetti S, Bettegazzi B J Cell Sci. 2024; 138(1).

PMID: 39648860 PMC: 11828468. DOI: 10.1242/jcs.263446.

SERCA Modulators Reveal Distinct Signaling and Functional Roles of T Lymphocyte Ca Stores.

Uddin M, Thomas D Int J Mol Sci. 2024; 25(22).

PMID: 39596161 PMC: 11593871. DOI: 10.3390/ijms252212095.

Enhanced Ca-Driven Arrhythmogenic Events in Female Patients With Atrial Fibrillation: Insights From Computational Modeling.

Zhang X, Wu Y, Smith C, Louch W, Morotti S, Dobrev D JACC Clin Electrophysiol. 2024; 10(11):2371-2391.

PMID: 39340505 PMC: 11602355. DOI: 10.1016/j.jacep.2024.07.020.

Effects of High-Dose Cyclophosphamide on Ultrastructural Changes and Gene Expression Profiles in the Cardiomyocytes of Mice.

Nishikawa T, Miyahara E, Yamazaki I, Ikawa K, Nakagawa S, Kodama Y Diseases. 2024; 12(5).

PMID: 38785740 PMC: 11120609. DOI: 10.3390/diseases12050085.

Isolation of the Sarcoplasmic Reticulum Ca-ATPase from Rabbit Fast-Twitch Muscle.

Rivera-Moran M, Sampedro J Methods Protoc. 2023; 6(5).

PMID: 37888034 PMC: 10608927. DOI: 10.3390/mps6050102.

References

Back S, Kaufman R . Endoplasmic reticulum stress and type 2 diabetes. Annu Rev Biochem. 2012; 81:767-93. PMC: 3684428. DOI: 10.1146/annurev-biochem-072909-095555. View

Inesi G, Tadini-Buoninsegni F . Ca(2+)/H (+) exchange, lumenal Ca(2+) release and Ca (2+)/ATP coupling ratios in the sarcoplasmic reticulum ATPase. J Cell Commun Signal. 2013; 8(1):5-11. PMC: 3972395. DOI: 10.1007/s12079-013-0213-7. View

Rasmussen U, Broogger Christensen S, Sandberg F . Thapsigargine and thapsigargicine, two new histamine liberators from Thapsia garganica L. Acta Pharm Suec. 1978; 15(2):133-40. View

Bilmen J, Khan S, Javed M, Michelangeli F . Inhibition of the SERCA Ca2+ pumps by curcumin. Curcumin putatively stabilizes the interaction between the nucleotide-binding and phosphorylation domains in the absence of ATP. Eur J Biochem. 2001; 268(23):6318-27. DOI: 10.1046/j.0014-2956.2001.02589.x. View

Moller J, Olesen C, Winther A, Nissen P . The sarcoplasmic Ca2+-ATPase: design of a perfect chemi-osmotic pump. Q Rev Biophys. 2010; 43(4):501-66. DOI: 10.1017/S003358351000017X. View

Bartolommei G, Tadini-Buoninsegni F, Moncelli M, Gemma S, Camodeca C, Butini S . The Ca2+-ATPase (SERCA1) is inhibited by 4-aminoquinoline derivatives through interference with catalytic activation by Ca2+, whereas the ATPase E2 state remains functional. J Biol Chem. 2011; 286(44):38383-38389. PMC: 3207476. DOI: 10.1074/jbc.M111.287276. View

Sadafi F, Massai L, Bartolommei G, Moncelli M, Messori L, Tadini-Buoninsegni F . Anticancer ruthenium(III) complex KP1019 interferes with ATP-dependent Ca2+ translocation by sarco-endoplasmic reticulum Ca2+-ATPase (SERCA). ChemMedChem. 2014; 9(8):1660-4. DOI: 10.1002/cmdc.201402128. View

Tadini-Buoninsegni F, Bartolommei G, Moncelli M, Fendler K . Charge transfer in P-type ATPases investigated on planar membranes. Arch Biochem Biophys. 2008; 476(1):75-86. DOI: 10.1016/j.abb.2008.02.031. View

Olesen C, Sorensen T, Nielsen R, Moller J, Nissen P . Dephosphorylation of the calcium pump coupled to counterion occlusion. Science. 2004; 306(5705):2251-5. DOI: 10.1126/science.1106289. View

10.

Cui C, Merritt R, Fu L, Pan Z . Targeting calcium signaling in cancer therapy. Acta Pharm Sin B. 2017; 7(1):3-17. PMC: 5237760. DOI: 10.1016/j.apsb.2016.11.001. View

11.

Pintschovius J, Fendler K, Bamberg E . Charge translocation by the Na+/K+-ATPase investigated on solid supported membranes: cytoplasmic cation binding and release. Biophys J. 1999; 76(2):827-36. PMC: 1300084. DOI: 10.1016/S0006-3495(99)77246-2. View

12.

BERMAN M, Karlish S . Interaction of an aromatic dibromoisothiouronium derivative with the Ca(2+)-ATPase of skeletal muscle sarcoplasmic reticulum. Biochemistry. 2003; 42(12):3556-66. DOI: 10.1021/bi026071n. View

13.

Ferrandi M, Barassi P, Tadini-Buoninsegni F, Bartolommei G, Molinari I, Tripodi M . Istaroxime stimulates SERCA2a and accelerates calcium cycling in heart failure by relieving phospholamban inhibition. Br J Pharmacol. 2013; 169(8):1849-61. PMC: 3753840. DOI: 10.1111/bph.12278. View

14.

Liu Y, Pilankatta R, Lewis D, Inesi G, Tadini-Buoninsegni F, Bartolommei G . High-yield heterologous expression of wild type and mutant Ca(2+) ATPase: Characterization of Ca(2+) binding sites by charge transfer. J Mol Biol. 2009; 391(5):858-71. PMC: 2928698. DOI: 10.1016/j.jmb.2009.06.044. View

15.

Wang D, Lippard S . Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005; 4(4):307-20. DOI: 10.1038/nrd1691. View

16.

Avellanal M, Rodriguez P, Barrigon S . Protective effects of cyclopiazonic acid on ischemia-reperfusion injury in rabbit hearts. J Cardiovasc Pharmacol. 1998; 32(5):845-51. DOI: 10.1097/00005344-199811000-00022. View

17.

Tadini-Buoninsegni F, Sordi G, Smeazzetto S, Natile G, Arnesano F . Effect of cisplatin on the transport activity of P-type ATPases. Metallomics. 2017; 9(7):960-968. DOI: 10.1039/c7mt00100b. View

18.

Dao T, Sehgal P, Tung T, Moller J, Nielsen J, Palmgren M . Demethoxycurcumin Is A Potent Inhibitor of P-Type ATPases from Diverse Kingdoms of Life. PLoS One. 2016; 11(9):e0163260. PMC: 5028038. DOI: 10.1371/journal.pone.0163260. View

19.

Turner H . Spiroindolone NITD609 is a novel antimalarial drug that targets the P-type ATPase PfATP4. Future Med Chem. 2016; 8(2):227-38. DOI: 10.4155/fmc.15.177. View

20.

Rocchetti M, Besana A, Mostacciuolo G, Micheletti R, Ferrari P, Sarkozi S . Modulation of sarcoplasmic reticulum function by Na+/K+ pump inhibitors with different toxicity: digoxin and PST2744 [(E,Z)-3-((2-aminoethoxy)imino)androstane-6,17-dione hydrochloride]. J Pharmacol Exp Ther. 2004; 313(1):207-15. DOI: 10.1124/jpet.104.077933. View